Blood clot-targeted nanoparticles
View Patent ↗Emulsions comprising nanoparticles formed from high boiling perfluorochemical substances, said particles coated with a lipid/surfactant coating are made target-specific by directly coupling said nanoparticles to a targeting ligand. The nanoparticles may further include biologically active agents, radionuclides, and/or other imaging agents.
1. A method to obtain a magnetic resonance image of a blood clot in a subject, which method comprises
administering to said subject an emulsion of nanoparticles, said nanoparticles consisting of liquid perfluorocarbon coated with lipid/surfactant,
wherein said nanoparticles are coupled to at least one targeting ligand that is specific for at least one component characterizing blood clots that binds specifically to fibrin, gpIIb/IIIa, tissue factor/VIIA complex, activated clotting factor Xa, activated clotting factor IXa, or the fibrin condensation product, d-dimer, and
wherein said nanoparticles are also coupled to at least one magnetic resonance imaging (MRI) contrast agent;
allowing the targeting ligand to bind to the blood clot; and
detecting a magnetic resonance image of said blood clot wherein said blood clot is bound to said ligand coupled directly to said lipid/surfactant-coated particles, while said nanoparticles are entirely in the liquid state.
2. The method of claim 1 , wherein said MRI contrast agent is a chelated paramagnetic ion.
3. The method of claim 2 , wherein the paramagnetic ion is gadolinium ion.
4. The method of claim 1 , wherein the perfluorocarbon is selected from the group consisting of perfluorodecalin, perfluorooctane, perfluorodichlorooctane, perfluoro-n-octyl bromide, perfluoroheptane, perfluorodecane, perfluorotripropylamine, perfluortributylamine, and mixtures thereof.
5. The method of claim 4 , wherein the perfluorocarbon is perfluoro-n-octyl bromide.
6. The method of claim 1 , wherein the targeting ligand is coupled covalently to a component of the lipid/surfactant coating.
7. The method of claim 1 , wherein the ligand binds specifically to fibrin.
8. The method of claim 7 , wherein said ligand is an antifibrin antibody or an immunoreactive fragment thereof.
9. The method of claim 1 , wherein the ligand binds specifically to gpIIb/IIIa.
10. The method of claim 1 , wherein the ligand binds specifically to tissue factor/VIIA complex.
11. The method of claim 1 , wherein the ligand binds specifically to activated clotting factor Xa.
12. The method of claim 1 , wherein the ligand binds specifically to activated clotting factor IXa.
13. The method of claim 1 , wherein the ligand binds specifically to fibrin condensation product, d-dimer.